

CORRECTION

Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiro Ozaki, Kazuoki Kondo, Toshifumi Hibi


An incorrect version of [S1 File](#) was published as two separate Supporting Information documents ([S1](#) and [S2 Files](#) in the original article) in error. Please view the correct [S1 File](#) below.

Supporting information

S1 File. Protocol summary in English.
(PDF)

Reference

1. Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, et al. (2018) Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. *PLoS ONE* 13(8): e0201956. <https://doi.org/10.1371/journal.pone.0201956> PMID: 30114224



OPEN ACCESS

Citation: Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, et al. (2022) Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. *PLoS ONE* 17(4): e0261932. <https://doi.org/10.1371/journal.pone.0261932>

Published: April 19, 2022

Copyright: © 2022 Tajiri et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.